Assessing the Relationship between Performance on the University of California Performance Skills Assessment (UPSA) and Outcomes in Schizophrenia: A Systematic Review and Evidence Synthesis

Shelagh Szabo,1 Elizabeth Merikle,2 Greta Lozano-Ortega,1 Lauren Powell,1 Thomas Macek,2 and Stephanie Cline2

1Broadstreet HEOR, Vancouver, BC, Canada
2Takeda Pharmaceuticals, Deerfield, IL, USA

Correspondence should be addressed to Stephanie Cline; sekirbach@gmail.com

Received 24 May 2018; Revised 12 November 2018; Accepted 5 December 2018; Published 27 December 2018

1. Introduction
Cognitive dysfunction has been recognized as a core feature of schizophrenia and an important determinant of health outcomes [1, 2]. The cognitive impacts of schizophrenia tend to be present at illness onset, remain relatively stable over time, and have a neutral response to the antipsychotic medications that are effective at treating other symptoms of schizophrenia [3–7]. Individual domains of cognitive ability (including learning, attention, and executive functioning), and composite scores on measures of these, are correlated with everyday functioning [8, 9]. As a result, cognitive dysfunction is thought to be a substantial contributor to the functional disability associated with schizophrenia.

It is not surprising, therefore, that, with the recent shift in the management of schizophrenia from symptom control to functional recovery, pharmacotherapies developed to treat cognition in schizophrenia are expected to demonstrate improvement on both cognitive and functional co-primary endpoints [2]. The psychometric characteristics and practicability of various performance-based measures of functional capacity in patients with schizophrenia have been assessed.
in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Validation of Intermediate Measures (VIM) study [2]. It concluded that the University of California at San Diego (UCSD) Performance-based Skills Assessment (UPSA) was the superior co-primary measure to be included in randomized trials [2]. The UPSA measures capacity in five domains of functioning, including household chores, communication, finance, transportation, and planning recreational activities, by scoring patients as they complete a series of simulated daily activities in a clinical setting [10]. UPSA performance is significantly impaired among individuals with schizophrenia or schizoaffective disorder compared with healthy controls [10] and is able to predict real-world functional outcomes [11, 12].

The UPSA is considered the standard performance-based measure of functional capacity among individuals with schizophrenia, as it provides a fair balance between ease of administration, reliability, and validity in relation to real-world functional outcomes [11, 12]. However, the strength of the relationship between the UPSA and real-world functional outcomes, and how it applies across the various functional measures used to measure treatment efficacy and effectiveness in schizophrenia, is not clear. Therefore, the objective of this study was to synthesize published evidence on how functional capacity, as measured by the UPSA, relates to other functional measures and real-world outcomes among individuals with schizophrenia. The findings from this study will highlight the strength of the evidence of the relationship between measures of functional capacity and functional outcomes in schizophrenia and identify knowledge gaps.

2. Methods

A systematic review of the published literature was conducted to identify studies in individuals diagnosed with schizophrenia on whom joint evaluations of functional capacity, measured using the UPSA, and a priori-determined key functional outcomes (functional scale measures; generic or disease-specific, health-related quality of life (HRQoL); employment status; residential status) were performed.

2.1. Search Strategy. The MEDLINE® and Embase® databases were searched using terms related to schizophrenia, the UPSA, and generic and specific functional measures and outcomes. Studies that matched the predetermined criteria according to a PICO(S) (Population, Intervention/Comparators, Outcomes, Study) approach (Table S1) were included in this review. Other evidence synthesis or decision-modeling studies or case reports were excluded. The literature review was limited to publications in English from 2000 to April 27, 2017, with a minimum sample size of ten participants.

2.2. Study Selection. Two researchers independently reviewed all abstracts identified by the search strategy against the PICO(S) criteria and then reviewed the full text of all potentially relevant abstracts. Discrepancies between the studies selected for inclusion by the two researchers were arbitrated by a third researcher.

2.3. Data Extraction. Study design, baseline clinical and demographic characteristics of the patient populations, and outcomes data of interest from the eligible studies were extracted into Excel®. Outcomes data included scores on the UPSA, HRQoL, other functional scale measures, and real-world outcomes such as residential and employment status. As the objective was to understand how the range of scores on each functional measure related to the range of UPSA scores, the focus was on measures where > two studies reported outcomes using that measure; measures with ≤ two sets of scores would not allow for meaningful comparison.

Where available, both baseline and final scores on functional measures were extracted, as well as changes in scores over time. For continuous variables, the mean, median, standard deviation, and range were extracted; for dichotomous and categorical variables, the number of patients and proportion were extracted.

2.4. Quality of Included Studies. The quality of the included studies was assessed using the Strengthening of Reporting in Observational Studies (STROBE) checklist (http://strobe-statement.org/index.php?id=available-checklists).

2.5. Statistical Analysis. The synthesis focused on the functional measures most frequently described in association with UPSA scores. For functional measures described in at least six studies, scatter plots of overall UPSA score versus the score on the functional measure were created. Pearson correlations were estimated between the functional measure score and the UPSA score: overall, and according to the type of UPSA used (full UPSA versus UPSA-Brief [UPSA-B]). These were estimated in R version 3.4.0, via the cor.test function, which also reported the statistical significance of the correlation coefficient. In this analysis, p values of 0.05 or lower were considered statistically significant, while those greater than 0.05 but lower than 0.1 were considered borderline statistically significant. Regardless of statistical significance, each correlation coefficient calculated was categorized as small (0.1-0.3), moderate (0.3-0.5), and large (>0.5) [13]. For measures described in ≤ five studies, associations with the UPSA were qualitatively described. Overall UPSA scores were imputed in studies that only reported subdomain UPSA scores or provided raw scores.

To evaluate real-world outcomes, the relationship between UPSA scores and current living situation or current employment status was assessed. Current living situation as presented by the original articles was recategorized into four groups based on level of care and supervision required: (1) living independently, defined as individuals residing in the community (alone, with a roommate, or with their family); (2) community-dwelling assisted living, defined as individuals residing in sheltered housing, board-and-care homes, and residential care homes; (3) restricted living, defined as individuals residing in locked board-and-care homes and restricted housing; and (4) institutionalized, defined as individuals being cared for in skilled-nursing homes and psychiatric hospitals. Current employment status, also presented by the original articles, was recategorized into...
three distinct groupings: (1) not employed; (2) employed, including full- or part-time paid employment; and (3) other, such as volunteers, students, sheltered employment, retired, and people on disability.

3. Results

The searches identified 3,245 articles. Titles and abstracts were screened, and 330 studies were considered potentially eligible for inclusion. Full-text articles were retrieved. After analyzing the full-text articles, 254 studies were excluded and 76 studies were found eligible for inclusion according to our criteria for considering studies in this review. These 76 studies provided 73 unique sets of data (subsequently referred to as studies) [2, 10, 14–84], because three of the studies presented evidence from samples already described in other included publications (Figure 1).

All 73 included studies reported the UPSA, 25 (34%) included studies reported the Specific Level of Function (SLOF), and >5% of the included studies reported the Global Assessment of Functioning (GAF), the Quality of Life Scale (QLS), the Multidimensional Scale of Independent Functioning (MSIF), and the Quality of Life Interview (QOLI) (Table 1). A brief description of the scales is presented in Table S2. Of the 73 included studies, 41 reported the full UPSA, 33 reported the UPSA-B, two reported the UPSA version 2 (UPSA-2), one reported the UPSA tablet/mobile application (UPSA-M) and UPSA-M-Brief, one reported the Computerized UPSA (C-UPSA), and one reported the UPSA-VIM. Only the full UPSA and UPSA-B provided a large enough evidence base (i.e., were reported on by ≥ six studies) for a quantitative assessment of the relationship between the UPSA and other functional measures, with a total of 68 studies reporting either of those measures, or both.

Characteristics of the included studies are presented in Table S3, and baseline characteristics of the patient populations in the included studies are presented in Table 2.

### 3.1. Study Quality Assessment

The quality assessment of the included studies was conducted according to the STROBE statement recommendation for reporting in observational studies (Table S4). Overall, the included studies had clearly defined objectives and presented detailed results of both primary and secondary objectives. They provided data sources as well as methods of assessment for each outcome reported. However, potential sources of bias were poorly reported, with only 9 out of the 73 studies addressing bias and any efforts to minimize it. Moreover, none of the included studies described how the study size was determined or whether power calculations were performed. Less than half (45%) of
Table 1: Availability of measures in the identified studies.

| Measure                                      | Studies that reported measure | N     | (%) |
|----------------------------------------------|-------------------------------|-------|-----|
| UCSD Performance-based Skills Assessment (UPSA) | 73                            | (100) |
| Full UPSA                                    | 41                            | (56)  |
| UPSA-B                                       | 33                            | (45)  |
| UPSA-2                                       | 2                             | (3)   |
| UPSA-M                                       | 1                             | (1)   |
| C-UPSA                                       | 1                             | (1)   |
| UPSA-VIM                                     | 1                             | (1)   |
| Specific Level of Function (SLOF)            | 25                            | (34)  |
| Global Assessment of Functioning (GAF)       | 11                            | (15)  |
| Quality of Life Scale (QLS)                  | 7                             | (10)  |
| Multidimensional Scale of Independent Functioning (MSIF) | 6                   | (8)   |
| Quality of Life Interview (QOLI)             | 5                             | (7)   |
| Strauss-Carpenter Level of Function          | 2                             | (3)   |
| Personal and Social Performance Scale (PSP)   | 2                             | (3)   |
| Role Functioning Scale (RFS)                 | 4                             | (5)   |
| Scale of Functioning (SOF)                   | 2                             | (3)   |
| Independent Living Skills Survey (ILSS)      | 2                             | (3)   |
| Social Functioning Scale (SFS)               | 3                             | (4)   |
| Quality of Well-being Scale (QWB)            | 2                             | (3)   |
| Independent Living Scale (ILS)               | 1                             | (1)   |
| Independent Living Skills Inventory (ILSI)    | 1                             | (1)   |
| Medical Outcomes Survey – Short-form 36 (SF-36)| 1                  | (1)   |
| Life Skills Profile (LSP)                    | 1                             | (1)   |
| Social Behavior Scale (SBS)                  | 1                             | (1)   |
| Residential Status - Outcome                 | 7                             | (10)  |
| Employment Status - Outcome                  | 5                             | (7)   |
| Residential Status - Baseline characteristics | 36                            | (49)  |
| Employment Status - Baseline characteristics  | 19                            | (26)  |

There were six studies that reported both the UPSA and the UPSA-B.

3.2. Quantitative Assessment of the Relationship between the UPSA and Other Functional Measures

3.2.1. UPSA versus SLOF. The UPSA and the SLOF were jointly evaluated in 25 studies. Quantitative assessment of the correlation between the UPSA and the SLOF was based on estimates from 18 studies, which reported the overall SLOF score, or enough information to derive it [17, 18, 20–24, 26–30, 34, 36, 56, 76, 79]. Of these, four studies reported the full length UPSA [20, 21, 24, 34], 13 studies reported the UPSA-B [17, 18, 22, 24, 26–30, 36, 56, 76], and one study reported the UPSA-VIM [79]. Baseline characteristics of the patient populations in these studies with respect to gender, age, ethnicity, and years of education were similar. Information on schizophrenia diagnosis (as opposed to schizoaffective disorder), antipsychotic use, living independently, and employment status was limited.

Quantitative analysis revealed a moderate, positive, borderline-significant Pearson correlation across these 18 studies of 0.45 ($p=0.06$) (Figure 2(a); Table S5).

3.2.2. UPSA versus GAF. The UPSA and the GAF were jointly evaluated in 11 studies [35, 37, 39–45, 47, 60]. Quantitative assessment of the correlation between the UPSA and the GAF was based on 11 pairs of estimates from nine studies, which reported the overall UPSA score, or enough information to derive it. Of these, six studies reported the UPSA [37, 40, 42, 43, 47, 60], and three studies reported the UPSA-B [35, 41, 45]. Baseline characteristics of the patient populations in these studies showed that the majority of studies included more males than females; two studies had samples with an average age < 30 years, while the rest of the studies had a mean age of ≥ 40 years. The proportion of patients with a schizophrenia diagnosis was comparable across studies. Information on ethnicity, years of education, antipsychotic use, and residential and employment status was limited.

Quantitative analysis demonstrated a moderate, negative, and nonsignificant Pearson correlation across all studies of -0.34 ($p=0.31$) (Figure 2(b); Table S6).

3.2.3. UPSA versus MSIF. The UPSA and the MSIF were jointly evaluated in six studies [52–57]. Quantitative assessment of the correlation between the UPSA and the MSIF was based on estimates from all six studies. Of these, five studies reported the UPSA [52–55, 57], and one study reported the UPSA-B [56]. Baseline characteristics of the patient populations in these studies with respect to gender and age were similar. Information on all other baseline characteristics was limited.

Quantitative analysis revealed a small nonsignificant Pearson correlation across all studies of 0.12 ($p=0.83$) (Figure 2(c); Table S7).

3.3. Qualitative Assessment of the Relationship between the UPSA and Other Functional Measures. Associations of the UPSA with functional measures reported in five or fewer studies were qualitatively described based on the authors’ considerations and findings. The UPSA and the QLS were jointly evaluated in seven studies [2, 39, 47, 58, 63, 76, 77]. Of these, four reported the full UPSA [2, 47, 58, 63], and three reported the UPSA-B [39, 76, 77]. Two studies could not be incorporated in a quantitative assessment of the relationship between the UPSA and the QLS, as one study reported a raw UPSA-B score [39] and one study did not report an overall UPSA score or information from which one could be derived.
### Table 2: Baseline characteristics of the patient populations in the identified studies.

| Study                        | N  | % Male | Age at baseline Mean (SD) | % Caucasian | Years of education Mean (SD) | % with schizophrenia diagnosis | Years since diagnosis | % Use of anti-psychotics |
|------------------------------|----|--------|----------------------------|-------------|------------------------------|-------------------------------|-----------------------|-------------------------|
| Gupta M et al., 2012         | 54 | NA     | 38 (9.3)                   | NA          | NA                           | 100                           | NA                    | NA                      |
| Twamley EW et al., 2002      | 111| 52     | 55 (9.6)                   | 75          | 13 (2.5)                     | 60                            | NA                    | 27                      |
| Mausbach BT et al., 2010     | 116| 60     | 50 (9.0)                   | NA          | 14 (2.4)                     | 100                           | NA                    | 93                      |
| Abram SV et al., 2014        | 59 | 63     | 35 (9.4)                   | 44          | NA                           | 100                           | NA                    | NA                      |
| Alden EC et al., 2015        | 36 | 61     | 37 (9.1)                   | NA          | 100                          | 100                           | NA                    | NA                      |
| Bowie CR et al., 2008        | 222| NA     | 57 (9.7)                   | NA          | 13 (2.5)                     | NA                            | NA                    | 100                     |
| Bowie CR et al., 2006        | 78 | NA     | 58 (7.3)                   | NA          | 13 (2.4)                     | 100                           | NA                    | 100                     |
| Bowie CR et al., 2007        | 67 | 76     | 59 (13.7)                  | 61          | 12 (1.7)                     | 76                            | NA                    | NA                      |
| Cardenas V et al., 2013      | 97 | 57     | 51 (6.5)                   | 50          | 12 (2.3)                     | 75                            | NA                    | NA                      |
| Depp CA et al., 2011         | 73 | 53     | 50 (6.3)                   | 45          | 12 (2.1)                     | NA                            | NA                    | 89                      |
| Depp CA et al., 2016         | 196| 62     | 52 (7.3)                   | 53          | 12 (2.3)                     | NA                            | NA                    | NA                      |
| Durand D et al., 2015        | 214| 65     | 41 (12.4)                  | 55          | 12 (2.2)                     | NA                            | NA                    | NA                      |
| Galderisi S et al., 2014     | 921| 70     | 40 (10.7)                  | NA          | 12 (3.4)                     | 100                           | NA                    | 97                      |
| Gold JM et al., 2012         | 114| 55     | 39 (11.5)                  | 57          | 13 (2.2)                     | NA                            | NA                    | NA                      |
| Gould F et al., 2012         | 194| 73     | 59 (79)                    | NA          | 12 (4.4)                     | NA                            | NA                    | 100                     |
| Harvey PD et al., 2009       | 146| 63     | 48 (11.9)                  | 100         | 14 (3.4)                     | NA                            | NA                    | 100                     |
| Harvey PD et al., 2009       | 236| 70     | 57 (7.3)                   | 64          | 13 (2.2)                     | NA                            | NA                    | 100                     |
| Ho JS et al., 2013           | 138| 67     | 51 (6.9)                   | 59          | NA                           | 84                            | NA                    | 100                     |
| Holshausen K et al., 2014    | 148| 72     | 56 (7.6)                   | 57          | 13 (2.5)                     | NA                            | NA                    | 100                     |
| Leifker FR et al., 2009      | 194| NA     | NA                         | NA          | NA                           | NA                            | NA                    | NA                      |
| Leung WW et al., 2008        | 230| 73     | 56 (9.9)                   | 60          | 13 (2.6)                     | 77                            | 28.4                  | NA                      |
| Olsson AK et al., 2012       | 211| 64     | 49 (11.6)                  | NA          | NA                           | 65                            | NA                    | NA                      |
| Smith MJ et al., 2012        | 46 | 65     | 35 (8.2)                   | NA          | 100                          | 100                           | NA                    | 100                     |
| Garcia-Portilla MP et al., 2013| 139| 73   | 40 (10.4)                  | NA          | NA                           | 100                           | NA                    | NA                      |
| Kim SJ et al., 2015          | 55 | 62     | 36 (6.9)                   | NA          | 13 (2.3)                     | 100                           | 11                    | 100                     |
| Ucok A et al., 2012          | 295| 45     | 42 (15.4)                  | NA          | 14 (4.2)                     | NA                            | NA                    | NA                      |
| Study                                      | N   | % Male | Age at baseline Mean (SD) | % Caucasian | Years of education Mean (SD) | % with schizophrenia diagnosis | Years since diagnosis | % Use of anti-psychotics |
|-------------------------------------------|-----|--------|----------------------------|-------------|-----------------------------|-------------------------------|----------------------|--------------------------|
| Bengoetxea E et al., 2014                 | 29  | 48     | 30 (9.2)                   | NA          | 9 (3.3)                     | NA                            | NA                   | NA                       |
| Lee J et al., 2015                        | 351 | 67     | 47 (11)                    | 55          | 12 (1.9)                    | NA                            | NA                   | NA                       |
| Light GA et al., 2005                     | 25  | 64     | 39 (9.6)                   | NA          | 12 (1.7)                    | 100                           | 17.7                 | 88                       |
| Light GA et al., 2012                     | 178 | 72     | 43 (10.1)                  | NA          | NA                          | NA                            | 21.9                 | NA                       |
| Musso MW et al., 2014                     | 18  | 89     | 38 (12.3)                  | 60          | NA                          | NA                            | NA                   | 100                      |
| Vesterager L et al., 2012                 | 117 | 54     | 25 (3.3)                   | NA          | NA                          | 84                            | NA                   | 89                       |
| Elliott CS et al., 2014                   | 71  | 75     | 48 (9.4)                   | NA          | 12 (1.9)                    | NA                            | NA                   | NA                       |
| Fiszdon JM et al., 2010                   | 48  | 81     | 49 (8.7)                   | 56          | 12 (1.8)                    | 83                            | NA                   | NA                       |
| Twamley EW et al., 2012                   | 69  | 65     | 46 (9.5)                   | 59          | 13 (1.7)                    | 54                            | 23.3                 | 94                       |
| Mausbach BT et al., 2008                  | 236 | 65     | 49 (7.3)                   | NA          | 80                          | NA                            | NA                   | NA                       |
| Narvaez JM et al., 2008                   | 88  | 67     | 47 (8.8)                   | 66          | 13 (2.4)                    | 42                            | 21.9                 | 92                       |
| Twamley EW et al., 2011                   | 89  | 65     | 47 (9.8)                   | 58          | 13 (1.9)                    | 51                            | 25.7                 | 88                       |
| Ammar N et al., 2014                      | 72  | 80     | 42 (9.8)                   | NA          | 13 (2.0)                    | NA                            | NA                   | NA                       |
| Heinrichs RW et al., 2010                 | 127 | 65     | 42 (9.0)                   | NA          | NA                          | NA                            | NA                   | 99                       |
| Heinrichs RW et al., 2006                 | 64  | 75     | 40 (8.9)                   | NA          | NA                          | NA                            | NA                   | 95                       |
| Muharib E et al., 2014                    | 35  | 80     | 31 (5.9)                   | 66          | 13 (2.5)                    | NA                            | 8.5                  | 92                       |
| Sheffield JM et al., 2014                 | 104 | 58     | 40 (11.9)                  | 61          | 13 (3.9)                    | NA                            | NA                   | NA                       |
| Silverstein SM et al., 2011               | 155 | 65     | 0 (0)                      | 48          | NA                          | 100                           | NA                   | NA                       |
| Green MF et al., 2011                     | 163 | 66     | 44 (10.1)                  | NA          | 12 (2.1)                    | 100                           | 20.3                 | NA                       |
| Roseman AS et al., 2008                   | 144 | 80     | 52 (8.6)                   | 55          | 12 (2.2)                    | 65                            | NA                   | NA                       |
| Adelsky MB et al., 2011                   | 50  | 48     | 58 (8.7)                   | 40          | 11 (2.7)                    | 100                           | NA                   | NA                       |
| Green MF et al., 2008                     | 176 | 76     | 44 (11.2)                  | 59          | 12 (2.4)                    | 86                            | NA                   | 97                       |
| Heldin L et al., 2012                     | 95  | 44     | 36 (8.2)                   | NA          | 11 (2.5)                    | NA                            | NA                   | NA                       |
| Jeste ND et al., 2005                     | 136 | 59     | 49 (7.5)                   | NA          | 11 (2.3)                    | 81                            | 23.0                 | NA                       |
| Kasckow J et al., 2007                    | 145 | 78     | 52 (145.0)                 | 56          | 12 (2.3)                    | 62                            | NA                   | NA                       |
| Keefe RS et al., 2006                     | 56  | 84     | 35 (9.8)                   | NA          | 12 (2.1)                    | 100                           | NA                   | 100                      |
| Mausbach BT et al., 2008                  | 434 | 66     | 50 (7.9)                   | 67          | 12 (2.4)                    | 77                            | NA                   | NA                       |
### Table 2: Continued.

| Study                          | N   | % Male | Age at baseline Mean (SD) | % Caucasian | Years of education Mean (SD) | % with schizophrenia diagnosis | Years since diagnosis | % Use of anti-psychotics |
|-------------------------------|-----|--------|---------------------------|-------------|-------------------------------|---------------------------------|-----------------------|-------------------------|
| Mausbach BT et al., 2011      | 367 | 63     | 51 (9.6)                  | NA          | NA                            | NA                              | NA                    | NA                      |
| McClure MM et al., 2013       | 46  | 61     | 38 (11.8)                 | NA          | NA                            | 0                               | NA                    | NA                      |
| Moore RC et al., 2015         | 21  | 55     | 51 (8.4)                  | 45          | 13 (1.9)                      | NA                              | NA                    | NA                      |
| Moore RC et al., 2013         | 21  | 76     | 55 (4.1)                  | 76          | 13 (2.1)                      | NA                              | NA                    | NA                      |
| Murthy NV et al., 2012        | 55* | 76     | 31 (70)                   | NA          | 12 (2.1)                      | 100                             | 29.4                  | NA                      |
| Patterson TL et al., 2001     | 50  | 42     | 56 (8.5)                  | 74          | 13 (2.3)                      | NA                              | NA                    | NA                      |
| Stergiopoulos V et al., 2011  | 51  | 71     | 40 (11.6)                 | 65          | 12 (2.6)                      | 70                              | NA                    | 71                      |
| Thorp SR et al., 2012         | 746 | NA     | 56 (7.8)                  | 68          | 12 (2.8)                      | NA                              | NA                    | NA                      |
| Twamley EW et al., 2012       | 30  | 54     | 52 (5.1)                  | 57          | 12 (2.7)                      | 32                              | 23.4                  | 89                      |
| Vahia IV et al., 2010         | 884 | 64     | 52 (8.3)                  | 64          | 12 (2.5)                      | NA                              | 24.9                  | NA                      |
| Strassnig MT et al., 2015     | 402 | 66     | 50 (5.1)                  | 57          | 12 (5.1)                      | 100                             | NA                    | NA                      |
| Sabbag S et al., 2011         | 193 | 69     | 44 (11.5)                 | 54          | 13 (2.4)                      | 100                             | NA                    | NA                      |
| Bechti M et al., 2017         | 79  | 62     | 41 (10.3)                 | NA          | NA                            | NA                              | 100                   | 100                     |
| Czaja SJ et al., 2017         | 77  | 73     | 54 (7.6)                  | 26          | NA                            | NA                              | 100                   | NA                      |
| Keefe RSE et al., 2016        | 158 | 56     | 43 (11.9)                 | 47          | 13 (2.0)                      | 100                             | NA                    | NA                      |
| Koshikawa Y et al., 2016      | 21  | 52     | 45 (11.1)                 | NA          | NA                            | 95                              | NA                    | NA                      |
| Lee J et al., 2017            | 60  | 53     | 64 (6.8)                  | 12 (3.1)    | NA                            | NA                              | NA                    | NA                      |
| Moore RC et al., 2015         | 34  | 55     | 44 (9.2)                  | 12 (2.4)    | NA                            | NA                              | 100                   | NA                      |
| Moore RC et al., 2015         | 435 | 64     | 50 (10.0)                 | 54          | 12 (2.0)                      | NA                              | NA                    | NA                      |
| Ventura J et al., 2016        | 205 | 61     | 52 (7.0)                  | 45          | 13 (1.8)                      | 69                              | NA                    | NA                      |
| Kumar S et al., 2016          | 98  | 70     | 25 (5.1)                  | NA          | NA                            | NA                              | NA                    | NA                      |

NA, not applicable; SD, standard difference.  
*Patients in Study 1.  
*Patients in Study 2.
Five studies reported correlations between UPSA and the QLS scores ranging from 0.15 to 0.29 [2, 47, 63, 76, 77]. The UPSA-B and the Strauss-Carpenter scale were jointly evaluated in two studies [35, 61]. One study reported a correlation between UPSA-B score and areas of housing, ability to work, and social contacts measured with the Strauss-Carpenter scale [35]. The UPSA and the Personal and Social Performance Scale (PSP) were jointly evaluated in two studies [37, 39]. One study reported a correlation between the two scales of 0.42 ($p<0.0001$) [37]. The full or brief UPSA and the Role Functioning Scale (RFS) were jointly evaluated in four studies [41, 45, 81, 83]. Only one study assessed the correlation between the two scales [83], reporting a value of 0.47. The full UPSA and the Independent Living Survey (ILSS) were jointly evaluated in two studies [46, 47]. One study reported a correlation between the two scales of 0.13 ($p=0.24$) and concluded that the UPSA did not correlate well with the ILSS [46]. The other study reported a correlation of 0.16 ($p=0.28$) [47]. The UPSA and the Social Functioning Scale (SFS) were jointly evaluated in three studies [60, 76, 80], two of which assessed the correlation between the two scales. One study reported a correlation between full UPSA and SFS scores of 0.29. The authors suggested that within-site community functioning homogeneity resulted in variability in the size of correlations across sites [60]. The other study reported a correlation between UPSA-B and SFS scores of 0.10 (self-reported SFS; $p>0.05$) and 0.24 (proxy SPS; $p<0.05$) [76]. The full UPSA and the Quality of Well-being Scale (QWB) were jointly evaluated in two studies [10, 74]. Only one assessed the correlation between the two scales [10], reporting a value of 0.28 ($p>0.05$). The UPSA and the Independent Living Skills Inventory (ILSI) were jointly evaluated in one study, which reported a correlation between the two scales of 0.40 ($p<0.001$) [64]. The UPSA and the Life Skills Profile (LSP) were jointly evaluated in one study, which reported a correlation between the two scales of 0.07 (self-reported) and 0.08 (proxy) ($p>0.05$) [76]. The UPSA and the Social Behavior Scale (SBS) were jointly evaluated in one study,
which reported a correlation between the two scales of 0.06 (self-reported) and 0.10 (proxy) \( (p>0.05) \) [76]. The UPSA and the Medical Outcomes Survey–Short-form 36 (SF-36) were jointly evaluated in one study, which reported a correlation between the full UPSA and SF-36 scores of 0.1 \( (p>0.05) \) [72].

3.4. Quantitative Assessment of the Relationship between the UPSA and Real-World Outcomes

3.4.1. UPSA versus Residential Status from Demographic Characteristics of the Study Sample. Quantitative assessment of the correlation between the UPSA and residential status at baseline incorporated estimates reported in 36 studies [10, 15, 16, 19, 23, 24, 29, 32, 34, 35, 37, 42, 45, 48–51, 59, 61–72, 76, 78, 80, 82, 84]. Of these, 20 studies reported the UPSA-B, and 15 studies reported the UPSA-2 [70].

Baseline characteristics of the patient populations in these studies with respect to age, schizophrenia diagnosis, years of education, proportion using antipsychotics, and proportion of Caucasian participants were similar, when reported. Information on employment status was limited and variable.

Quantitative analysis revealed a moderate borderline-significant correlation between UPSA score and residential status, as described by the proportion of patients living independently, across all studies \( (0.31; \rho=0.65) \) (Figure 3(a); Table S8). There was a large, significant correlation between full UPSA score and the proportion of patients living independently \( (0.65; p<0.01) \), but a small, nonsignificant correlation between UPSA-B score and proportion of patients living independently \( (0.26; p=0.37) \).

3.4.2. UPSA versus Employment Status from Demographic Characteristics of the Study Sample. Quantitative assessment of the correlation between the UPSA and employment status at baseline incorporated estimates reported in 19 studies \( [16, 19, 26, 29, 34, 35, 37, 39, 50, 52, 55, 61, 66, 70, 71, 76, 78, 79] \). Of these studies, eight reported the UPSA [19, 23, 34, 37, 50, 52, 55, 71], nine the UPSA-B [16, 26, 29, 35, 39, 61, 66, 76, 78], one the UPSA-2 [70], and one the UPSA-VIM [79]. Baseline characteristics of the patient populations in these studies with respect to age, gender, ethnicity, and schizophrenia diagnosis were similar, when reported.

Quantitative analysis revealed no correlation between UPSA score and employment status, as described by the proportion of patients living independently, across all studies \( (0.04; p=0.88) \) (Figure 3(b); Table S9). There was a small nonsignificant correlation between full UPSA score and proportion with employment \( 0.22 (p=0.60) \) and a small nonsignificant correlation between UPSA-B score and proportion with employment \( 0.11 (p=0.80) \).

3.5. Qualitative Assessment of the Relationship between the UPSA and Real-World Outcomes

3.5.1. Residential Status as an Outcome. Seven studies investigated the correlation of the UPSA with current living situation \( [15, 16, 42, 49, 66, 67, 71] \). Some findings supported the utility of the UPSA as a proxy for assessing real-world functioning, reporting correlations between UPSA total score and degree of independence in community living of 0.48 \( (p<0.001) \) and 0.44 \( (p<0.05) \) [15, 42]. Other studies concluded that UPSA score did not significantly correlate with independent living. One study reported a correlation of 0.21 that was not statistically significant [67]. Another study included homeless and housed individuals with schizophrenia; there was no significant difference between housed and homeless groups in total UPSA score, which may have been due to small sample size [71]. Two studies indicated that the UPSA-B was useful for predicting residential status among individuals with schizophrenia based on regression analyses that showed a significant relationship \( [16, 66] \). One study indicated that the UPSA was significantly better than chance and better than classical clinical features of schizophrenia (e.g., positive and negative symptoms and global cognitive functioning) at predicting residential independence [49].

3.5.2. Employment Status as an Outcome. Five studies investigated the correlation of the UPSA with employment status \( [16, 66, 67, 72, 73] \). Two studies estimated correlations of the UPSA with employment status \( [72, 73] \). One reported correlations between UPSA total score and attainment of competitive work, weeks of competitive work, and wages from competitive work at 0.04 to 0.10; none of these correlations were statistically significant [73]. The other reported a correlation between UPSA score and employment status at 0.19 \( (p<0.01) \) [72]. Three studies investigated the use of the UPSA-B for predicting employment status \( [16, 66, 67] \). One reported a correlation between UPSA-B score and number of hours worked per week at 0.43 \( (p=0.001) \), concluding that being employed did not correlate with the UPSA-B, but hours of employment per week did [16]. Another reported a correlation between UPSA-B score and employment status of 0.09 \( (p>0.05) \) [67].

The strength of the relationships between the measures examined quantitatively (employment status, residential status, the SLOF, the GAF, and MSIF) and UPSA is depicted in Figure 4, stratified according to UPSA type.

4. Discussion

This systematic literature review and evidence synthesis from 73 articles evaluated how functional capacity, as measured by the UPSA, relates to other functional measures and real-world outcomes among individuals with schizophrenia. Understanding this relationship is critical to determine the usefulness of performance on functional capacity measures as potential outcome measures in schizophrenia clinical trials.

Correlations between the UPSA and functional measures were estimated where at least six studies jointly evaluated both measures. Sufficient evidence to assess correlation with the UPSA, across and within studies, was only available for the SLOF, the GAF, and the MSIF. With respect to the SLOF, the current study provided evidence of a moderate correlation with the UPSA \( (p=0.45; p=0.06) \). This is consistent with findings from the individual studies that reported
Scatterplot of UPSA scores and proportion living independently across studies that reported baseline residential status. 36 studies were included in the analyses; 33 data points are shown as three studies reported 0 patients living independently (Adelsky, 2010; Stergiopoulos, 2011; Keefe 2006).

Scatterplot of UPSA scores and proportion with employment across studies that reported working status at baseline. 19 studies were included in the analyses: 17 data points are shown as one study reported 0 patients employed (Ucok, 2012) and another did not report the proportion of patients employed (Keefe, 2016).

Figure 3: UPSA vs residential and employment status.

Figure 4: The strength of correlations between UPSA and employment status, residential status, the SLOF, MSIF, and GAF. Strength of correlations indicated by a correlation coefficient (according to UPSA type, if sufficient data are available) and color. The number of studies contributing evidence to a particular relationship is indicated by the thickness of the line connecting the UPSA to each of the other measures.
on this relationship, with correlations that were statistically significant, ranging from 0.19 [76] to 0.57 [36]. Some of the studies that investigated the correlation between the UPSA and the SLOF explored differences between the self-reported and proxy-reported SLOF and indicated that the UPSA correlated with the SLOF-proxy (particularly when the SLOF was reported by the clinician), but not with the self-reported SLOF [25, 76]. Based on these findings, we focused on the SLOF reported by proxy, which was used most frequently in the investigations of association between the UPSA and the SLOF, to avoid incorporation of heterogeneity in the estimates.

For the GAF, the MSIF, the QLS, the Strauss-Carpenter, the PSP, and the ILSI, there was evidence from study authors’ assessments that these functional measures do correlate with the UPSA, although the current study was not able to demonstrate similar findings when grouping results. Of these measures, the GAF and the QLS showed the strongest correlations, which were consistently reported in two [35, 42] and five [2, 47, 58, 76, 77] studies, respectively. In the current study, the correlation between the UPSA and the GAF was not statistically significant, and in the opposite direction of the expected association. This counterintuitive estimate may have resulted from study heterogeneity or sparsity of evidence. However, the high degree of underreporting of baseline characteristics other than age and gender did not enable an accurate assessment of study heterogeneity.

The correlation of the UPSA with real-world functional outcomes, specifically the ability to live independently and to work, was investigated. The UPSA, particularly the full UPSA versus the UPSA-B, correlated well with residential status, specifically the proportion of individuals living independently. In contrast, authors of individual studies using the UPSA-B found good correlations with residential status [16]. Undetected heterogeneity may explain why this relationship was not observed when aggregating across studies.

The current study found no association between the UPSA and ability to work. These findings were consistent with those reported by other authors who have investigated these relationships within their own studies. Interestingly, one study found a moderate correlation between the UPSA and hours worked per week ($\rho=0.43; p=0.001$) and concluded that while hours of employment correlated well with the UPSA-B, being employed did not [16]. Authors of these studies did not provide further comment regarding the lack of association between the UPSA and ability to work.

While the available data were limited, the observed correlations between the UPSA, most functional measures, and residential status support the value of use of assessments of functional capacity to track functional status among patients in trials of schizophrenia treatments. This is important because although there are limitations to the use of functional simulation measures like the UPSA, they were developed, at least in part, to address challenges inherent in other measures of functional status for measuring outcomes in schizophrenia trials. For example, changes in real-world community functioning would be very compelling, but are unlikely to be observed over the course of a randomized trial in response to a particular treatment [2, 85]. Interviewer-based measures can also be limited as many behaviours cannot naturally be observed under such settings. Similarly, self-report can be unreliable among members of many patient groups, including among those with schizophrenia; and many schizophrenia sufferers do not have close informants to provide proxy reports [11]. Additionally, the different measures of functional status for schizophrenia all include slightly different combinations of constructs within their measure; this may in part affect the degree of any relationship observed with performance on the UPSA.

Of course, there are situations where a real-world outcome or another functional measure may be most appropriate compared to the UPSA; and ultimately, measure selection should be driven by a number of factors including trial/study duration, the severity of the patient population included, and the need for comparability of the study findings with the results of other studies.

5. Limitations
A key strength of the current study is that a comprehensive, systematic approach to identifying and synthesizing all relevant articles where the UPSA was evaluated along with another functional measure was undertaken. Estimating correlations based on data presented for a particular measure across a number of different studies is a novel approach that aims to fill a gap in the current knowledge regarding how well assessments of functional capacity in schizophrenia correlate with other functional measures and real-world functional outcomes. However, this study was associated with some limitations. First, as with any systematic review, the findings were limited by the heterogeneity in the design, validity, and reporting of the studies contributing estimates. Second, several studies by the same study groups had slightly differing baseline characteristics and sample sizes, but it was unclear whether these studies were using the same study sample. Third, there was heterogeneity in the reported scores for the functional measures. In some instances, overall scores were imputed, some studies did not allow for score imputation, and some authors reported raw scores or z-scores that could not be used for assessing correlations between the UPSA and the functional measures. Fourth, living situation and employment status were presented idiosyncratically across studies; therefore, comparability of these results was facilitated by creating standardized categories. Fifth, aggregated data was summarized across studies, which is prone to ecological bias. Metaregression could have been used to adjust functional estimates for differences in study characteristics, but there were insufficient data to conduct such analyses. Sixth, changes in the correlation of the UPSA with functional measures overtime could not be assessed, as most studies were cross-sectional (at least with respect to measuring functional status), and the few that were longitudinal did not evaluate measures of interest. Finally, conclusions about which functional measures correlate best with the UPSA are based on the amount of evidence available to investigate those associations at present; further research is required to

Schizophrenia Research and Treatment
fully understand the value of functional measures with little published data.

6. Conclusion

This review provides data on the association between functional capacity, as measured by the UPSA, and other functional measures in schizophrenia, and the strength of those associations. Of all the functional measures considered, the amount of evidence was greatest for the relationship between the UPSA and the SLOF, and the SLOF has the strongest observed correlation with the UPSA. Authors of studies that evaluated the GAF and the QLS found that these measures correlated well with the UPSA. Although evidence supports a relationship between the UPSA and functional measures that assess real-world outcomes in patients with schizophrenia, further evaluation of these relationships is needed in order to maximize their implementation in trials, as well as determine the need for and inform the subsequent development of new assessments. Regardless, the findings of this study may help inform the design of upcoming trials of schizophrenia treatments, as well as contribute to the framework for understanding the clinical and economic value of emerging treatments.

Disclosure

This study was funded by Takeda Pharmaceuticals. At the time of study development and manuscript development, Drs. Cline, Merikle, and Macek were employees of Takeda Pharmaceuticals. Broadstreet HEOR received funding from the study sponsor to conduct the study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All authors contributed to the study design, data analysis, and principal writing of the manuscript.

Acknowledgments

The authors would like to thank Jane Kondejewski, Ph.D., of Snell Medical Communications, for assistance in drafting the manuscript, based on discussion and feedback from all the authors.

Supplementary Materials

Supplementary Table 1: criteria to define the scope of the systematic literature review. Supplementary Table 2: description of and references for scales to measure function among patients with schizophrenia. Supplementary Table 3: design characteristics of the studies included in the systematic review. Supplementary Table 4: mean (SD) scores on, and correlations between, the UPSA and the SLOF. Supplementary Table 5: mean (SD) scores on, and correlations between, the UPSA and the GAF. Supplementary Table 6: mean (SD) scores on, and correlations between, the UPSA and MSIF. Supplementary Table 7: study samples according to baseline residential status and mean (SD) UPSA score. Supplementary Table 8: study samples according to baseline employment status and mean (SD) UPSA score. Supplementary Table 9: STROBE statement checklist for included studies. (Supplementary Materials)

References

[1] J. L. Reilly and J. A. Sweeney, “Generalized and specific neurocognitive deficits in psychotic disorders: Utility for evaluating pharmacological treatment effects and as intermediate phenotypes for gene discovery,” Schizophrenia Bulletin, vol. 40, no. 3, pp. 516–522, 2014.
[2] M. F. Green, N. R. Schooler, R. S. Kern et al., “Evaluation of functionally meaningful measures for clinical trials of cognitive enhancement in schizophrenia,” The American Journal of Psychiatry, vol. 168, no. 4, pp. 400–407, 2011.
[3] C. R. Bowie and P. D. Harvey, “Cognitive deficits and functional outcome in schizophrenia,” Neuropsychiatric Disease and Treatment, vol. 2, no. 4, pp. 531–536, 2006.
[4] C. R. Bowie, A. Reichenberg, M. M. McClure, W. L. Leung, and P. D. Harvey, “Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: Differential sensitivity of clinical neuropsychological and experimental information processing tests,” Schizophrenia Research, vol. 106, no. 1, pp. 50–58, 2008.
[5] M. F. Green, “What are the functional consequences of neurocognitive deficits in schizophrenia?” The American Journal of Psychiatry, vol. 153, no. 3, pp. 321–330, 1996.
[6] S. Hill, “Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia,” Schizophrenia Research, vol. 68, no. 1, pp. 49–63, 2004.
[7] R. S. E. Keefe, J. A. Sweeney, H. Gu et al., “Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison,” The American Journal of Psychiatry, vol. 164, no. 7, pp. 1061–1071, 2007.
[8] M. F. Green, R. S. Kern, D. L. Braff, and J. Mintz, “Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘right stuff?’” Schizophrenia Bulletin, vol. 26, no. 1, pp. 119–136, 2000.
[9] M. M. McClure, C. R. Bowie, T. L. Patterson et al., “Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: Evidence for specificity of relationships?” Schizophrenia Research, vol. 89, no. 1-3, pp. 330–338, 2007.
[10] T. L. Patterson, S. Goldman, C. L. McBibbin, T. Hughes, and D. V. Jeste, “UCSD Performance-Based Skills Assessment: Development of a New Measure of Everyday Functioning for Severely Mentally Ill Adults,” Schizophrenia Bulletin, vol. 27, no. 2, pp. 235–245, 2001.
[11] P. D. Harvey, D. I. Velligan, and A. S. Bellack, “Performance-based measures of functional skills: Usefulness in clinical treatment studies,” Schizophrenia Bulletin, vol. 33, no. 5, pp. 1138–1148, 2007.
C. R. Bowie, A. Reichenberg, T. L. Patterson, R. K. Heaton, and C. A. Depp, A. L. Harmell, I. V. Vahia, and B. T. Mausbach, "Neurocognitive and functional correlates of mobile phone use in middle-aged and older patients with schizophrenia," *Aging & Mental Health*, vol. 20, no. 1, pp. 29–35, 2016.

C. A. Depp, V. Cardenas, S. Harris, I. V. Vahia, T. L. Patterson, and B. T. Mausbach, "Psychopathological and functional correlates of behavioral activation and avoidance in schizophrenia," *The Journal of Nervous and Mental Disease*, vol. 199, no. 11, pp. 861–865, 2011.

C. A. Depp, A. L. Harmell, I. V. Vahia, and B. T. Mausbach, "Neurocognitive and functional correlates of mobile phone use in middle-aged and older patients with schizophrenia," *Aging & Mental Health*, vol. 20, no. 1, pp. 29–35, 2016.

D. Durand, M. Strassnig, S. Sabbag et al., "Factors influencing self-assessment of cognition and functioning in schizophrenia: Implications for treatment studies," *European Neuropsychopharmacology*, vol. 25, no. 2, pp. 185–191, 2015.

S. Galderisi, A. Rossi, P. Rocca et al., "The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia," *World Psychiatry*, vol. 13, no. 3, pp. 275–287, 2014.

J. M. Gold, D. M. Barch, C. S. Carter et al., "Clinical, functional, and intertask correlations of measures developed by the cognitive neuroscience test reliability and clinical applications for schizophrenia consortium," *Schizophrenia Bulletin*, vol. 38, no. 1, pp. 144–152, 2012.

F. Gould, C. R. Bowie, and P. D. Harvey, "The influence of demographic factors on functional capacity and everyday functional outcomes in schizophrenia," *Journal of Clinical and Experimental Neuropsychology*, vol. 34, no. 5, pp. 467–475, 2012.

P. D. Harvey, L. Heldin, C. R. Bowie et al., "Performance-based measurement of functional disability in schizophrenia: A cross-national study in the United States and Sweden," *The American Journal of Psychiatry*, vol. 166, no. 7, pp. 821–827, 2009.

P. D. Harvey, R. S. E. Keefe, T. L. Patterson, R. K. Heaton, and C. R. Bowie, "Abbreviated neuropsychological assessment in schizophrenia: Prediction of different aspects of outcome," *Journal of Clinical and Experimental Neuropsychology*, vol. 31, no. 4, pp. 462–471, 2009.

J. S. Ho, R. C. Moore, T. Davine et al., "Direct and mediated effects of cognitive function with multidimensional outcome measures in schizophrenia: The role of functional capacity," *Journal of Clinical and Experimental Neuropsychology*, vol. 35, no. 8, pp. 882–895, 2013.

K. Holshausen, C. R. Bowie, B. T. Mausbach, T. L. Patterson, and P. D. Harvey, "Neurocognition, functional capacity, and functional outcomes: The cost of inexperience," *Schizophrenia Research*, vol. 152, no. 2–3, pp. 430–434, 2014.

F. R. Leifker, C. R. Bowie, and P. D. Harvey, "Determinants of everyday outcomes in schizophrenia: The influences of cognitive impairment, functional capacity, and symptoms," *Schizophrenia Research*, vol. 115, no. 1, pp. 82–87, 2009.

W. W. Leung, C. R. Bowie, and P. D. Harvey, "Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study," *Journal of the International Neuropsychological Society*, vol. 14, no. 3, pp. 479–488, 2008.

A.-K. Olsson, L. Heldin, F. Härttahg, and T. Norlander, "Psychometric properties of a performance-based measurement of functional capacity, the UCSD Performance-based Skills Assessment - Brief version," *Psychiatry Research*, vol. 197, no. 3, pp. 290–294, 2012.

M. J. Smith, W. P. Horan, T. M. Karpouzian, S. V. Abram, D. J. Cobia, and J. G. Csernansky, "Self-reported empathy deficits are uniquely associated with poor functioning in schizophrenia," *Schizophrenia Research*, vol. 137, no. 1–3, pp. 196–202, 2012.

M. P. Garcia-Portilla, J. J. Gomar, M. T. Bobes-Bascaran et al., "Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder," *Schizophrenia Research*, vol. 150, no. 2–3, pp. 421–426, 2013.

S. Kim, J. Shim, B. Kong et al., "Differences in cognitive function and daily living skills between early- and late-stage schizophrenia," *International Journal of Psychiatry in Clinical Practice*, vol. 19, no. 4, pp. 245–251, 2014.

A. Üçok, P. Gorwood, and G. Karadayi, "Employment and its relationship with functionality and quality of life in patients with schizophrenia: EGOFORS Study," *European Psychiatry*, vol. 27, no. 6, pp. 422–425, 2012.

E. Bengoetxea, C. Z. Burton, B. T. Mausbach, T. L. Patterson, and E. W. Twamley, "The effect of language on functional
capacity assessment in middle-aged and older US Latinos with schizophrenia,” Psychiatry Research, vol. 218, no. 1-2, pp. 31–34, 2014.

[41] J. Lee, M. F. Green, M. E. Calkins et al., “Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) Study: The moderating role of smoking status and antipsychotic medications,” Schizophrenia Research, vol. 163, no. 1-3, pp. 24–31, 2015.

[42] G. A. Light and D. L. Braff, “Mismatch negativity deficits are associated with poor functioning in schizophrenia patients,” Archives of General Psychiatry, vol. 62, no. 2, pp. 127–136, 2005.

[43] G. A. Light, N. R. Swerdlow, A. J. Rissling et al., “Characterization of Neuropsychiologic and Neuropsychological Biomarkers for Use in Genomic and Clinical Outcome Studies of Schizophrenia,” PLoS ONE, vol. 7, no. 7, p. e39434, 2012.

[44] M. W. Musso, A. S. Cohen, T. L. Auster, and J. E. McGovern, “Investigation of the Montreal Cognitive Assessment (MoCA) as a cognitive screener in severe mental illness,” Psychiatry Research, vol. 220, no. 1-2, pp. 664–668, 2014.

[45] L. Vesterager, T. Ø. Christensen, B. B. Olsen et al., “Cognitive and clinical predictors of functional capacity in patients with first episode schizophrenia,” Schizophrenia Research, vol. 141, no. 2-3, pp. 251–256, 2012.

[46] C. S. Elliott and J. M. Fiszdon, “Comparison of self-report and performance-based measures of everyday functioning in individuals with schizophrenia: Implications for measure selection,” Cognitive Neuropsychiatry, vol. 19, no. 6, pp. 485–494, 2014.

[47] J. M. Fiszdon and J. K. Johannesen, “Functional significance of preserved affect recognition in schizophrenia,” Psychiatry Research, vol. 176, no. 2-3, pp. 120–125, 2010.

[48] E. W. Twamley, L. Vella, C. Z. Burton, R. K. Heaton, and D. V. Jeste, “Compensatory cognitive training for psychosis: effects in a randomized controlled trial,” Journal of Clinical Psychiatry, vol. 73, no. 9, pp. 1212–1219, 2012.

[49] B. T. Mausbach, C. R. Bowie, P. D. Harvey et al., “Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia,” Journal of Psychiatric Research, vol. 42, no. 4, pp. 320–327, 2008.

[50] J. M. Narvaez, E. W. Twamley, C. L. McKibbin, R. K. Heaton, and T. L. Patterson, “Subjective and objective quality of life in schizophrenia,” Schizophrenia Research, vol. 98, no. 1-3, pp. 201–208, 2008.

[51] E. W. Twamley, C. Z. Burton, and L. Vella, “Compensatory cognitive training for psychosis: Who stays in treatment?” Schizophrenia Bulletin, vol. 37, no. 2, pp. 555–562, 2011.

[52] N. Ammari, R. Walter Heinrichs, F. Pinnock, A. A. Miles, E. Muharib, and S. M. Vaz, “Preserved, deteriorated, and premorbidly impaired patterns of intellectual ability in schizophrenia,” Neuropsychology, vol. 28, no. 3, pp. 353–358, 2014.

[53] R. W. Heinrichs, N. Ammari, A. A. Miles, and S. McDermid Vaz, “Cognitive performance and functional competence as predictors of community independence in schizophrenia,” Schizophrenia Bulletin, vol. 36, no. 2, pp. 381–387, 2010.

[54] R. W. Heinrichs, M. Statucka, J. Goldberg, and S. McDermid Vaz, “The University of California Performance Skills Assessment (UPSA) in schizophrenia,” Schizophrenia Research, vol. 88, no. 1-3, pp. 135–141, 2006.

[55] E. Muharib, R. W. Heinrichs, A. Miles, F. Pinnock, S. McDermid Vaz, and N. Ammari, “Community outcome in cognitively normal schizophrenia patients,” Journal of the International Neuropsychological Society, vol. 20, no. 8, pp. 805–811, 2014.

[56] J. M. Sheffield, J. M. Gold, M. E. Strauss et al., “Common and specific cognitive deficits in schizophrenia: Relationships to function,” Cognitive, Affective & Behavioral Neuroscience, vol. 14, no. 1, pp. 161–174, 2014.

[57] S. M. Silverstein, S. D. All, and J. Jaeger, “Cognition-UPSA score relationships: A further analysis of Silverstein et al. (2010) data and some caveats,” Psychiatry Research, vol. 187, no. 3, pp. 424–431, 2011.

[58] A. S. Roseman, J. Kasckow, I. Fellows et al., “Insight, quality of life, and functional capacity in middle-aged and older adults with schizophrenia,” International Journal of Geriatric Psychiatry, vol. 23, no. 7, pp. 760–765, 2008.

[59] M. B. Adelsky, C. R. Bowie, T. E. Goldberg, and M. R. Serper, “Adaptive competence impairment and cognitive deficits in acutely Ill Schizophrenia patients residing in nursing homes,” The American Journal of Geriatric Psychiatry, vol. 19, no. 8, pp. 752–756, 2011.

[60] M. F. Green, K. H. Nuechterlein, R. S. Kern et al., “Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS Psychometric and Standardization Study,” The American Journal of Psychiatry, vol. 165, no. 2, pp. 221–228, 2008.

[61] L. Helldin, R. Cavallaro, S. Galderisi, “A functional comparison of patients with schizophrenia between the North and South of Europe,” European Psychiatry, vol. 27, no. 6, pp. 442–444, 2012.

[62] N. D. Jeste, D. J. Moore, S. R. Goldman et al., “Predictors of Everyday Functioning Among Older Mexican Americans vs. Anglo-Americans With Schizophrenia,” Journal of Clinical Psychiatry, vol. 66, no. 10, pp. 1304–1311, 2005.

[63] J. Kasckow, L. Montross, S. Golshan et al., “Suicidality in middle-aged and older patients with schizophrenia and depressive symptoms: Relationship to functioning and quality of life,” International Journal of Geriatric Psychiatry, vol. 22, no. 12, pp. 1223–1228, 2007.

[64] R. S. E. Keeffe, M. Poe, T. M. Walker, and P. D. Harvey, “The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome,” Journal of Clinical and Experimental Neuropsychology, vol. 28, no. 2, pp. 260–269, 2006.

[65] B. T. Mausbach, C. A. Depp, V. Cardenas, D. V. Jeste, and T. L. Patterson, “Relationship between functional capacity and community responsibility in patients with schizophrenia: Differences between independent and assisted living settings,” Community Mental Health Journal, vol. 44, no. 5, pp. 385–391, 2008.

[66] B. T. Mausbach, C. A. Depp, C. R. Bowie et al., “Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia,” Schizophrenia Research, vol. 132, no. 2-3, pp. 165–170, 2011.

[67] M. M. McClure, P. D. Harvey, C. R. Bowie, B. Iacoviello, and L. J. Siever, “Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder,” Schizophrenia Research, vol. 144, no. 1-3, pp. 146–150, 2013.

[68] R. C. Moore, P. L. Fazeli, T. L. Patterson et al., “UPSA-M: Feasibility and initial validity of a mobile application of the UCSD Performance-Based Skills Assessment,” Schizophrenia Research, vol. 164, no. 1-3, pp. 187–192, 2015.

[69] R. C. Moore, A. L. Harmell, J. Ho et al., “Initial validation of a computerized version of the UCSD Performance-Based Skills
Assessment (C-UPSA) for assessing functioning in schizophrenia,” *Schizophrenia Research*, vol. 144, no. 1-3, pp. 87–92, 2013.

[70] N. V. Murthy, H. Mahncke, B. E. Wexler et al., “Computerized cognitive remediation training for schizophrenia: An open label, multi-site, multinational methodology study,” *Schizophrenia Research*, vol. 139, no. 1-3, pp. 87–91, 2012.

[71] V. Stergiopoulos, T. Burra, S. Rourke, and S. Hwang, “Housing status as an independent predictor of functional capacity in patients with schizophrenia,” *The Journal of Nervous and Mental Disease*, vol. 199, no. 11, pp. 854–860, 2011.

[72] S. R. Thorp, H. M. Sones, D. Glorioso et al., “Older Patients With Schizophrenia: Does Military Veteran Status Matter?” *The American Journal of Geriatric Psychiatry*, vol. 20, no. 3, pp. 248–256, 2012.

[73] E. W. Twamley, L. Vella, C. Z. Burton, D. R. Becker, M. D. Bell, and D. V. Jeste, “The efficacy of supported employment for middle-aged and older people with schizophrenia,” *Schizophrenia Research*, vol. 135, no. 1-3, pp. 100–104, 2012.

[74] I. V. Vahia, B. W. Palmer, C. Depp et al., “Is late-onset schizophrenia a subtype of schizophrenia?” *Acta Psychiatrica Scandinavica*, vol. 122, no. 5, pp. 414–426, 2010.

[75] M. T. Strassnig, T. Raykov, C. O’Gorman et al., “Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity,” *Schizophrenia Research*, vol. 165, no. 1, pp. 76–82, 2015.

[76] S. Sabbag, E. M. Twamley, L. Vella, R. K. Heaton, T. L. Patterson, and P. D. Harvey, “Assessing everyday functioning in schizophrenia: Not all informants seem equally informative,” *Schizophrenia Research*, vol. 131, no. 1-3, pp. 250–255, 2011.

[77] M. Bechi, M. Bosia, M. Spangaro et al., “Exploring functioning in schizophrenia: Predictors of functional capacity and real-world behaviour,” *Psychiatry Research*, vol. 251, pp. 118–124, 2017.

[78] S. I. Czaja, D. A. Loewenstein, C. C. Lee, S. H. Fu, and P. D. Harvey, “Assessing functional performance using computer-based simulations of everyday activities,” *Schizophrenia Research*, vol. 183, pp. 130–136, 2017.

[79] R. S. E. Keefe, V. G. Davis, A. S. Atkins et al., “Validation of a Computerized test of Functional Capacity,” *Schizophrenia Research*, vol. 175, no. 1-3, pp. 90–96, 2016.

[80] Y. Koshikawa, Y. Takekita, M. Kato et al., “The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: A 6-month, open-label, randomized controlled pilot trial,” *Neuropsychobiology*, vol. 73, no. 1, pp. 35–42, 2016.

[81] J. Lee, S. Rizzo, L. Altshuler et al., “Deconstructing Bipolar Disorder and Schizophrenia: A cross-diagnostic cluster analysis of cognitive phenotypes,” *Journal of Affective Disorders*, vol. 209, pp. 71–79, 2017.

[82] R. C. Moore, A. L. Harmell, P. D. Harvey et al., “Improving the understanding of the link between cognition and functional capacity in schizophrenia and bipolar disorder,” *Schizophrenia Research*, vol. 169, no. 1-3, pp. 121–127, 2015.

[83] J. Ventura, K. L. Subotnik, A. Ered, G. S. Hellemann, and K. H. Nuechterlein, “Cognitive Assessment Interview (CAI): Validity as a co-primary measure of cognition across phases of schizophrenia,” *Schizophrenia Research*, vol. 172, no. 1-3, pp. 137–142, 2016.

[84] S. Kumar, B. H. Mulsant, C. Tsoutsoulas et al., “An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia,” *International Journal of Geriatric Psychiatry*, vol. 31, no. 10, pp. 1116–1123, 2016.